Investigational drug · Phase 2
KH631
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Age-Related Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "KH631"
First trial start
2023
Feb 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KH631", any sponsor or status.
Conditions studied
As listed on its trial records.
- Age-Related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "KH631" as an intervention, largest first.
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT05672121 · 42 participants (planned) · Start Feb 6, 2023 · Primary completion Dec 28, 2026
Drug: KH631 · For: Age-Related Macular Degeneration
Sites: Beijing, China
- Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular DegenerationActive, not recruiting
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT05657301 · 25 participants (planned) · Start Oct 16, 2023 · Primary completion Sep 2026
Drug: KH631 · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Lemont, Illinois; Boston, Massachusetts · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond.
Rowe LW, Ciulla TA · Genes (Basel) 2024
- Preclinical evaluation of KH631, a novel rAAV8 gene therapy product for neovascular age-related macular degeneration.
Ke X, Jiang H, Li Q, et al. · Mol Ther 2023
Also in development for Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- KH658Phase 21 trial
Chengdu Origen Biotechnology Co., Ltd. · Age-related Macular Degeneration
- SOM-401Phase 21 trial
Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration
- VOY-101Phase 21 trial
Perceive Biotherapeutics, Inc. · Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.